Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FUCA1 | P04066 | 2/20 | 0.63 |
| ▸ | GBA1 | P04062 | 1/20 | 0.62 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.59 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.56 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.54 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.54 |
| ▸ | CCR3 | P51677 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL51716 | 0.94 | FUCA1 (0.58) | FUCA1GBA1CYP2D6SIGMAR1S1PR1 | |
| SCHEMBL63432 | 0.94 | FUCA1 (0.58) | FUCA1GBA1CYP2D6SIGMAR1S1PR1 | |
| SCHEMBL5640368 | 0.92 | CYP2D6 (0.65) | FUCA1GBA1CYP2D6SIGMAR1CCR3 | |
| SCHEMBL8545766 | 0.87 | CYP2D6 (0.68) | CYP2D6SIGMAR1CCR3ALDH1A1CXCR4 | |
| SCHEMBL5968994 | 0.87 | CYP2D6 (0.68) | CYP2D6SIGMAR1CCR3ALDH1A1CXCR4 | |
| SCHEMBL1386235 | 0.87 | CYP2D6 (0.68) | CYP2D6SIGMAR1CCR3ALDH1A1CXCR4 | |
| SCHEMBL14759418 | 0.86 | GBA1 (0.75) | FUCA1GBA1SIGMAR1S1PR1S1PR5 | |
| SCHEMBL1190716 | 0.86 | GBA1 (0.75) | FUCA1GBA1SIGMAR1S1PR1S1PR5 | |
| SCHEMBL742926 | 0.86 | GBA1 (0.75) | FUCA1GBA1SIGMAR1S1PR1S1PR5 | |
| SCHEMBL14759416 | 0.86 | GBA1 (0.75) | FUCA1GBA1SIGMAR1S1PR1S1PR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8283345-B2 | Azetidine analogues of nucleosidase and phosphorylase inhibitors | INDUSTRIAL RESEARCH LIMITED (NZ) | 2012-10-09 | — | — | US | disclosed |
| US-20100168141-A1 | AZETIDINE ANALOGUES NUCLEOSIDASE AND PHOSPHORYLASE INHIBITORS | ALBERT EINSTEIN COLLEGE OF MEDICINE | 2010-07-01 | — | — | US | disclosed |
| EP-0190786-B1 | AZETIDINE DERIVATIVES; PROCESS FOR THEIR PREPARATION; AND THEIR USE AS INTERMEDIATES | SHELL INTERNATIONALE RESEARCHMAATSCHAPPIJ B.V. (NL) | 1990-04-04 | — | — | EP | disclosed |
| US-4855452-A | N-substituted azetidine carboxylate derivatives | SHELL OIL COMPANY (US) | 1989-08-08 | — | — | US | disclosed |
| US-4778577-A | OXIDATION OF ALCOHOL TO ACID WITH NICKEL/III/COMPOUND | SHELL OIL COMPANY (US) | 1988-10-18 | — | — | US | disclosed |
| EP-0221579-A1 | A process for the preparation of an azetidine-3-carboxylic acid or salt thereof | SHELL INTERNATIONALE RESEARCHMAATSCHAPPIJ B.V. (NL) | 1987-05-13 | — | — | EP | disclosed |
| US-4634554-A | N-benzyl,3-hydroxymethyl and 3-alkanoyloxymethyl azetidine derivatives | SHELL OIL COMPANY (US) | 1987-01-06 | — | — | US | disclosed |
| EP-0199413-A2 | Process for preparing azetidine derivatives and novel intermediates therein | SHELL INTERNATIONALE RESEARCHMAATSCHAPPIJ B.V. (NL) | 1986-10-29 | — | — | EP | disclosed |
| EP-0190786-A1 | Azetidine derivatives; process for their preparation; and their use as intermediates | SHELL INTERNATIONALE RESEARCHMAATSCHAPPIJ B.V. (NL) | 1986-08-13 | — | — | EP | disclosed |
| EP-0140437-A2 | Substituted azetidine derivatives, process for their preparation, and their use as intermediates | SHELL INTERNATIONALE RESEARCHMAATSCHAPPIJ B.V. (NL) | 1985-05-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100168141-A1 | AZETIDINE ANALOGUES NUCLEOSIDASE AND PHOSPHORYLASE INHIBITORS | PNP, SNRPD2, SRR | FUCA1 423/4885GBA1 621/4885CYP2D6 101/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.